NCT04563247View on ClinicalTrials.gov

Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs

CompletedOBSERVATIONAL
Enrollment

970

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

February 8, 2021

Study Completion Date

February 8, 2021

Conditions
Covid19
Interventions
DIAGNOSTIC_TEST

IgG SARS CoV 2 antibodies

The asymptomatic healthcare workers of high exposure COVID19 areas will be tested for IgG SARS CoV 2 antibodies

Trial Locations (1)

54500

Lahore General Hospital, Lahore

All Listed Sponsors
lead

Lahore General Hospital

OTHER_GOV

NCT04563247 - Seroprevalence of SARS-CoV-2 in Asymptomatic Frontline COVID-19 HCWs | Biotech Hunter | Biotech Hunter